These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33282106)

  • 41. Laser and light therapies for acne rosacea.
    Butterwick KJ; Butterwick LS; Han A
    J Drugs Dermatol; 2006 Jan; 5(1):35-9. PubMed ID: 16468290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
    Baumann L; Goldberg DJ; Stein Gold L; Tanghetti EA; Lain E; Kaufman J; Weng E; Berk DR; Ahluwalia G
    J Drugs Dermatol; 2018 Mar; 17(3):290-298. PubMed ID: 29537447
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advances in pharmacotherapy for rosacea: what is the current state of the art?
    Dall'Oglio F; Nasca MR; Gerbino C; Micali G
    Expert Opin Pharmacother; 2022 Nov; 23(16):1845-1854. PubMed ID: 36330970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ocular rosacea: an update on pathogenesis and therapy.
    Stone DU; Chodosh J
    Curr Opin Ophthalmol; 2004 Dec; 15(6):499-502. PubMed ID: 15523195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interventions for rosacea.
    van Zuuren EJ; Fedorowicz Z; Carter B; van der Linden MM; Charland L
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD003262. PubMed ID: 25919144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Managing Rosacea in the Clinic: From Pathophysiology to Treatment-A Review of the Literature.
    Johnson SM; Berg A; Barr C
    J Clin Aesthet Dermatol; 2020 Apr; 13(4 Suppl):S17-S22. PubMed ID: 32802248
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Topical Timolol 0.5% in the Treatment of Acne and Rosacea: A Multicentric Study.
    Al Mokadem SM; Ibrahim AM; El Sayed AM
    J Clin Aesthet Dermatol; 2020 Mar; 13(3):22-27. PubMed ID: 32308793
    [No Abstract]   [Full Text] [Related]  

  • 48. New and Emerging Treatments for Rosacea.
    Gold LM; Draelos ZD
    Am J Clin Dermatol; 2015 Dec; 16(6):457-61. PubMed ID: 26396117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acne and rosacea. New and emerging therapies.
    Thiboutot DM
    Dermatol Clin; 2000 Jan; 18(1):63-71, viii. PubMed ID: 10626112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Devices and topical agents for rosacea management.
    Mansouri Y; Goldenberg G
    Cutis; 2014 Jul; 94(1):21-5. PubMed ID: 25101340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis.
    Siddiqui K; Stein Gold L; Gill J
    Springerplus; 2016; 5(1):1151. PubMed ID: 27504249
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Status report from the American Acne & Rosacea Society on medical management of acne in adult women, part 3: oral therapies.
    Del Rosso JQ; Harper JC; Graber EM; Thiboutot D; Silverberg NB; Eichenfield LF
    Cutis; 2015 Dec; 96(6):376-82. PubMed ID: 26761932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging.
    King S; Campbell J; Rowe R; Daly ML; Moncrieff G; Maybury C
    J Cosmet Dermatol; 2023 Oct; 22(10):2650-2662. PubMed ID: 37550898
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New developments in the treatment of rosacea - role of once-daily ivermectin cream.
    Cardwell LA; Alinia H; Moradi Tuchayi S; Feldman SR
    Clin Cosmet Investig Dermatol; 2016; 9():71-7. PubMed ID: 27051311
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rosacea.
    Searle T; Al-Niaimi F; Ali FR
    Br J Hosp Med (Lond); 2021 Feb; 82(2):1-8. PubMed ID: 33646026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxymetazoline and Energy-Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open-Label, Interventional Study.
    Tanghetti EA; Goldberg DJ; Dover JS; Geronemus RG; Bai Z; Alvandi N; Shanler SD
    Lasers Surg Med; 2021 Jan; 53(1):55-65. PubMed ID: 32378241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0.
    Tanghetti EA; Dover JS; Goldberg DJ; Dhawan SS; Luo L; Berk DR; Ahluwalia G; Alvandi N
    J Drugs Dermatol; 2018 Jun; 17(6):621-626. PubMed ID: 29879249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee.
    Gallo RL; Granstein RD; Kang S; Mannis M; Steinhoff M; Tan J; Thiboutot D
    J Am Acad Dermatol; 2018 Jan; 78(1):148-155. PubMed ID: 29089180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments.
    Steinhoff M; Vocanson M; Voegel JJ; Hacini-Rachinel F; Schäfer G
    Adv Ther; 2016 Sep; 33(9):1481-501. PubMed ID: 27432381
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Topical a-Agonist Therapy for Persistent Facial Erythema of Rosacea and the Addition of Oxmetazoline to the Treatment Armamentarium: Where Are We Now?
    Del Rosso JQ
    J Clin Aesthet Dermatol; 2017 Jul; 10(7):28-32. PubMed ID: 29104721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.